Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Italy Largo Francesco Vito 1, 00168 Rome, Italy

About the sponsor

Clinical research in ovarian cancer, fallopian tube cancer, and primary peritoneal cancer includes advanced, recurrent, platinum-resistant, and HRD-guided treatment strategies, as well as studies in patients with disease involving the pelvis and peritoneum.

  • Advanced and recurrent ovarian malignancies
  • Platinum-resistant disease
  • Pelvic exenteration in gynecologic cancer
  • Pre-neoplastic vulvar and cervical lesions
  • Vulvar Paget's disease

Interest also extends to electrochemotherapy, pembrolizumab-based approaches, and biomarker-informed management of HPV-related and invasive gynecologic lesions.

About Specializations

Fondazione Policlinico Universitario Agostino Gemelli IRCCS runs clinical trials in conditions such as Ovarian cancer, Fallopian tube cancer, Transitional cell carcinoma, Malignant peritoneal neoplasm, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

26 clinical trials

Uveal melanoma

Recruiting

Study on Tebentafusp and Liver Radiotherapy for Patients with Metastatic Uveal Melanoma HLA A*02:01 Positive

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Depression

Recruiting

Study on Brain Activity in Treatment-Resistant Depression Using [18F]MC225 for Patients with Depression

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:[18F]Mc225
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Metastatic renal cell carcinoma

Recruiting

Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Pancreatic carcinoma

Recruiting

Study on the Effectiveness of Paclitaxel and Gemcitabine for Patients with Pancreatic Cancer Spread to the Abdomen

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Bladder cancer

Recruiting

Study on Cisplatin, Nab-paclitaxel, and Nivolumab with Radiotherapy for Patients with Non-Metastatic Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Hormone-refractory prostate cancer

Recruiting

Study Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Obesity

Recruiting

Study of esomeprazole effects on endoscopic sleeve gastroplasty structural integrity in obese patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Esomeprazole
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Pelvic exenteration

Recruiting

Study on Indocyanine Green for Evaluating Blood Flow in Surgery for Women with Recurrent or Persistent Gynecological Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Autoimmune disorder

Recruiting

Study on Anti-CD19 CAR T-Cell Therapy for Patients with Refractory Systemic Autoimmune Diseases Using Levetiracetam, Fludarabine, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Type 2 diabetes mellitus

Recruiting

Comparison of dapagliflozin and oral semaglutide effectiveness in type 2 diabetes patients based on insulin resistance or secretion deficit

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Transitional cell carcinoma

Not yet recruiting

ctDNA‑guided Study of Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Hepatic cirrhosis+1

Not yet recruiting

Study of Tinzaparin Sodium to Prevent Venous Thromboembolism in Adults with Liver Cirrhosis and Hepatocellular Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tinzaparin Sodium
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.